132 related articles for article (PubMed ID: 37406290)
1. Updates in the Use of Immunohistochemical Stains in Breast and Gynecologic Pathology.
Jenkins TM; Mehr CR
Arch Pathol Lab Med; 2024 Jan; 148(1):33-47. PubMed ID: 37406290
[TBL] [Abstract][Full Text] [Related]
2. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma.
Ronchi A; Pagliuca F; Zito Marino F; Accardo M; Cozzolino I; Franco R
Semin Cancer Biol; 2021 Jul; 72():114-122. PubMed ID: 32165319
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
Tang P; Tse GM
Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
[TBL] [Abstract][Full Text] [Related]
4. Review of estrogen receptor, progesterone receptor, and HER-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution.
Jorns JM; Healy P; Zhao L
Arch Pathol Lab Med; 2013 Nov; 137(11):1660-3. PubMed ID: 24168506
[TBL] [Abstract][Full Text] [Related]
5. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
6. Use of Immunohistochemical Stains in Epithelial Lesions of the Breast.
Khazai L; Rosa M
Cancer Control; 2015 Apr; 22(2):220-5. PubMed ID: 26068768
[TBL] [Abstract][Full Text] [Related]
7. [Updated CAP guidelines for determining molecular biological subtypes of breast cancer].
Zavalishina LE; Oliushina EM; Andreeva YY; Kuznetsova OA; Moskvina LV; Frank GA
Arkh Patol; 2023; 85(4):39-46. PubMed ID: 37530189
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
9. Correlation of expression of hormone and HER2 receptors with various clinico-pathological prognostic parameters and with each other in malignant breast lesion.
Mohanty SS
Ann Diagn Pathol; 2021 Feb; 50():151659. PubMed ID: 33249360
[TBL] [Abstract][Full Text] [Related]
10. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates.
Rakha EA; Chmielik E; Schmitt FC; Tan PH; Quinn CM; Gallagy G
Pathobiology; 2022; 89(5):263-277. PubMed ID: 35728576
[TBL] [Abstract][Full Text] [Related]
12. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2.
Bagaria SP; Ray PS; Sim MS; Ye X; Shamonki JM; Cui X; Giuliano AE
JAMA Surg; 2014 Feb; 149(2):125-9. PubMed ID: 24306257
[TBL] [Abstract][Full Text] [Related]
13. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens.
Hariri N; Hasteh F; Walavalkar V; Roma AA; Fadare O
Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):1-7. PubMed ID: 28549033
[TBL] [Abstract][Full Text] [Related]
17. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Mahtani R; Holmes FA; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Vogel C;
Clin Breast Cancer; 2020 Jun; 20(3):e251-e260. PubMed ID: 32139271
[TBL] [Abstract][Full Text] [Related]
18. ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR
Kar A; Koto K; Walker D; Trudeau T; Edgerton S; Thor A; Gutierrez-Hartmann A
Breast Cancer Res Treat; 2020 Aug; 182(3):601-612. PubMed ID: 32562116
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
